120 Participants Needed

Behavioral Weight Loss Intervention + Cardiac Rehab for Atrial Fibrillation and Obesity

(BeWEL IN CR-AF Trial)

TC
BM
BV
Overseen ByBraiden Valdarchi, BSc
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Calgary
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether combining weight-loss classes with cardiac rehab can help individuals with both atrial fibrillation (a heart rhythm problem) and obesity feel better and potentially correct their heart rhythm. The focus is on whether losing at least 10% of body weight can improve symptoms for those with both conditions. Participants will either engage in traditional cardiac rehab or the same rehab plus weight-loss classes (Behavioral Weight Loss Therapy) that teach healthy weight management strategies. This study might suit individuals with atrial fibrillation, classified as obese, and leading a sedentary lifestyle. As an unphased trial, it offers a unique opportunity to explore innovative strategies for improving heart health and weight management.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking GLP-1 receptor agonists.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that behavioral weight loss programs and cardiac rehabilitation are safe for individuals. These treatments aid in weight loss and enhance heart health without causing major issues.

Behavioral weight loss programs use group classes to change thoughts and behaviors for weight loss. Studies have found that patients tolerate this method well, with no serious side effects.

Cardiac rehabilitation includes exercise sessions supervised by health professionals and is also safe. Research indicates it can help with heart rhythm problems like atrial fibrillation and improve fitness without increasing health risks.

Overall, both behavioral weight loss programs and cardiac rehabilitation are safe options for improving heart health and losing weight.12345

Why are researchers excited about this trial?

Researchers are excited about the combination of Behavioral Weight Loss Intervention (BWLT) and Cardiac Rehab (CR) for people with atrial fibrillation and obesity because it takes a unique approach by integrating weight management directly into cardiac rehabilitation. Unlike standard cardiac rehab programs that focus mainly on improving cardiovascular fitness, this new method adds weekly behavioral weight loss classes, aiming to address obesity as a key factor in overall heart health. This dual-focus strategy could potentially enhance the effectiveness of cardiac rehab by simultaneously tackling weight loss, which may improve atrial fibrillation management and overall patient outcomes.

What evidence suggests that this trial's treatments could be effective for atrial fibrillation and obesity?

Research shows that losing weight can help manage symptoms of atrial fibrillation (AF), a heart condition. People with obesity who lose about 10% of their body weight often experience fewer AF symptoms. In this trial, participants in the intervention arm will join a behavioral weight loss program combined with cardiac rehab. Studies have shown that this combination helps patients lose more weight than cardiac rehab alone. Another study suggested that this approach can also reduce the impact of AF. Overall, losing weight through these methods may improve heart rhythm and ease AF symptoms.12367

Who Is on the Research Team?

TC

Tavis Campbell, PhD

Principal Investigator

University of Calgary

Are You a Good Fit for This Trial?

This trial is for adults over 18 with atrial fibrillation or flutter and obesity (BMI ≥30), leading a sedentary lifestyle. They must speak English and be open to weight loss treatment, but can't have done similar programs or had bariatric surgery recently, nor should they have uncontrolled heart issues or be on certain medications.

Inclusion Criteria

I experience sudden or ongoing irregular heartbeats.
I do not exercise for at least 150 minutes a week.
I have at least one condition like sleep apnea, diabetes, high blood pressure, heart failure, high cholesterol, heart disease, or artery problems.
See 3 more

Exclusion Criteria

I am scheduled for a procedure to correct my irregular heartbeat.
I am currently on GLP-1 receptor agonist medication.
I had or will have weight-loss surgery within a year of joining the study.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants engage in a 12-week outpatient cardiac rehabilitation program with or without additional weekly behavioural weight loss classes

12 weeks
24 visits (in-person)

Follow-up

Participants are monitored for weight loss, AF burden, and other health outcomes

40 weeks
3 visits (in-person)

Long-term Follow-up

Participants' weight loss and AF symptoms are assessed at 52 weeks post-randomization

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • BWLT
  • CR
Trial Overview The study tests if adding a 'small changes' behavioural weight-loss program to standard cardiac rehab helps patients with atrial fibrillation and obesity lose more weight. Participants will either do regular exercise sessions in cardiac rehab or combine this with online group therapy classes for weight loss.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Group II: ControlExperimental Treatment1 Intervention

BWLT is already approved in Canada, United States for the following indications:

🇨🇦
Approved in Canada as Behavioural Weight Loss Treatment for:
🇺🇸
Approved in United States as Behavioural Weight Loss Treatment for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Alberta Health services

Collaborator

Trials
168
Recruited
658,000+

University of British Columbia

Collaborator

Trials
1,506
Recruited
2,528,000+

Published Research Related to This Trial

A randomized controlled trial showed that 88 patients with morbid obesity lost an average of 15% of their body weight after 12 months of personalized cognitive-behavioral therapy for obesity (CBT-OB), with no weight regain observed between 6 and 12 months.
In a real-world clinical setting, 77 patients who completed group CBT-OB achieved a 9.9% weight loss after 18 months, indicating that CBT-OB may be more effective than traditional weight-loss programs.
Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures.Dalle Grave, R., Sartirana, M., Calugi, S.[2020]
In a pilot study involving 38 adults with coronary heart disease (CHD) and obesity, adding a behavioral weight loss intervention to standard cardiac rehabilitation (CR) significantly improved weight loss (6.4% vs. 1.2%) and fat loss compared to CR alone.
The intervention was well-received, with a high retention rate of 95% and 98% attendance at weight loss sessions, indicating that integrating weight management into CR is both feasible and beneficial for enhancing self-efficacy and weight management behaviors.
Targeting Obesity to Optimize Weight Loss in Cardiac Rehabilitation: A PILOT STUDY.Brinkley, TE., Hsu, FC., Bowman, BM., et al.[2023]
In a study of 29,601 obese patients undergoing cardiac rehabilitation, the average weight loss was modest, with men losing 0.9 kg and women losing 0.5 kg, highlighting the challenge of achieving significant weight loss in this population.
Certain characteristics, such as smoking cessation, diabetes, and low fitness levels, were found to predict less weight loss, while higher initial weight and being employed were associated with greater weight loss, suggesting that personalized approaches to weight management in cardiac rehabilitation could be beneficial.
Obese patients' characteristics and weight loss outcomes in cardiac rehabilitation: An observational study of registry data.Wilkinson, JA., Harrison, AS., Doherty, P.[2021]

Citations

Weight reduction interventions for the management of atrial ...To evaluate the efficacy of weight loss interventions as adjunctive treatment for reducing atrial fibrillation burden.
Behavioural Weight Loss Treatment for Patients with Atrial ...Study Plan · Weight Loss, Patients will be weighed before and after the 12 week intervention and weight loss calculated in kilograms · Atrial Fibrillation Symptom ...
A randomized controlled trial of a “Small Changes” behavioral ...The addition of behavioral weight loss treatment (BWLT) to CR has been shown to produce greater weight loss among patients with obesity relative ...
Lifestyle and Risk Factor Modification for Reduction of ...For overweight or obese patients with AF, data suggest targeting at least a 10% reduction in weight to effect reductions in AF burden. •.
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39394158/
study protocol for the BE-WEL in CR-AF studyThis RCT protocol will evaluate the efficacy of a "Small Changes" behavioral weight loss treatment (BWLT) to produce clinically relevant (≥ 10%) weight loss ...
Behavioral Weight Loss Intervention + Cardiac Rehab for ...Behavioral weight loss interventions and cardiac rehabilitation programs have been shown to be safe for humans, with studies indicating they can lead to weight ...
Patient-Delivered Continuous Care for Weight Loss ...This randomized clinical trial examines the efficacy of an entirely patient-delivered treatment for weight loss maintenance compared with ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security